Flatiron Health has revealed a new collaboration agreement with Penn Medicine's Abramson Cancer Center (ACC) to introduce Flatiron Assist™, an advanced cancer care insights tool, to oncology care clinicians. This partnership aims to empower ACC clinicians by enabling them to access site-preferred treatment pathways and open clinical trials seamlessly alongside the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) during patient care. The primary objective is to enhance the delivery of evidence-based care, boost health equity, improve patient experiences, and reduce healthcare costs.

Flatiron Assist™ is a specialized clinical decision support platform for oncology, seamlessly integrated into electronic health records (EHRs). It provides up-to-date evidence-based medical practices, site-specific treatment pathways, and clinical research information to assist clinicians in making informed decisions during patient care. This includes NCCN Guidelines for the 26 most common cancers, site-specific treatment pathways, and relevant clinical trial data.

Significantly, Flatiron Assist™ has achieved high adoption rates among healthcare providers, resulting in positive outcomes for cancer centers. These outcomes include an impressive 88% adherence to NCCN guidelines¹ and a notable 44% reduction in the use of unique treatment regimens across cancer centers².

The collaboration's goals encompass deploying Flatiron Assist™ with NCCN-preferred guidelines across all diseases and developing ACC-preferred pathways for specialized diseases. Furthermore, Flatiron Assist™ records an impressive 84% selection rate of site-preferred regimens among its users at cancer centers³.The initiative will also explore the potential of using Flatiron Assist™ technology to raise awareness of available clinical trial opportunities and boost user adoption and satisfaction. 

Source: businesswire.com